Multimodality therapy for patients with high-risk prostate cancer: Current status and future directions

Seminars in Oncology

Volumn 40, Issue 3, 2013, Pages 308-321

  Zaorsky, Nicholas G ^a   Trabulsi, Edouard J ^a   Lin, Jianqing ^a   Den, Robert B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ABIRATERONE; ABIRATERONE ACETATE; ARAGON; ASP 9521; AZD 509; BEVACIZUMAB; BUPARLISIB; CABAZITAXEL; CABOZANTINIB; CALCITRIOL; CIXUTUMUMAB; CUSTIRSEN; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; EPI 001; ESTRAMUSTINE; EVEROLIMUS; EZN 4176; GALETERONE; IPILIMUMAB; MITOXANTRONE; ODM 201; ORTERONEL; PAZOPANIB; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; RAPAMYCIN; SIPULEUCEL T; SORAFENIB; TEMSIROLIMUS; TRILOSTANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CONSENSUS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SYSTEMIC THERAPY;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANDROGEN; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84879427246     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.04.006     Document Type: Article

References (104)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 1 2012 10 29
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 11 1998 969 974
3. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 3 2001 876 881
4. J.L. Mohler The 2010 NCCN clinical practice guidelines in oncology on prostate cancer J Natl Compr Canc Netw 8 2 2010 145
5. M. Han, A.W. Partin, C.R. Pound, J.I. Epstein, and P.C. Walsh Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience Urol Clin North Am 28 3 2001 555 565
6. A.V. D'Amico, K. Cote, M. Loffredo, A.A. Renshaw, and D. Schultz Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer J Clin Oncol 20 23 2002 4567 4573
7. A.V. D'Amico, J. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era J Clin Oncol 21 11 2003 2163 2172
8. Yossepowitch O, Eggener SE, Bianco FJ, Jr., et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol.;178(2):493-9.
9. B.M. Mian, P. Troncoso, and K. Okihara Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone J Urol 167 4 2002 1675 1680
10. G.W. Hull, F. Rabbani, F. Abbas, T.M. Wheeler, M.W. Kattan, and P.T. Scardino Cancer control with radical prostatectomy alone in 1,000 consecutive patients J Urol 167 2 Pt 1 2002 528 534
11. S.J. Freedland, E.B. Humphreys, L.A. Mangold, M. Eisenberger, and A.W. Partin Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality J Urol 176 4 Pt 1 2006 1404 1408
12. A. Patel, F. Dorey, J. Franklin, and J.B. deKernion Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen J Urol 158 4 1997 1441 1445
13. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 6 2000 1632 1642
14. B.A. Jereczek-Fossa, and R. Orecchia Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer Radiother Oncol 84 2 2007 197 215
15. E.J. Trabulsi, R.K. Valicenti, and A.L. Hanlon A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer Urology 72 6 2008 1298 1302
16. M.S. Anscher Salvage radiotherapy for recurrent prostate cancer: the earlier the better JAMA 291 11 2004 1380 1382
17. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 3 2009 956 962
18. M. Bolla, H. Van Poppel, and B. Tombal 10-Year results of adjuvant radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911) Int J Rad Biol Phys 78 3 2010 S29
19. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 18 2009 2924 2930
20. T. Daly, B.E. Hickey, M. Lehman, D.P. Francis, and A.M. See Adjuvant radiotherapy following radical prostatectomy for prostate cancer Cochrane Database Syst Rev 12 2011 CD007234
21. R.K. Valicenti, I. Chervoneva, and L.G. Gomella Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer Int J Radiat Oncol Biol Phys 58 4 2004 1093 1097
22. S.J. Buskirk, T.M. Pisansky, and S.E. Schild Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system J Urol 176 3 2006 985 990
23. R. Cheung, A.M. Kamat, and R. de Crevoisier Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy Int J Radiat Oncol Biol Phys 63 1 2005 134 140
24. S.B. Hayes, and A. Pollack Parameters for treatment decisions for salvage radiation therapy J Clin Oncol 23 32 2005 8204 8211
25. C. Parker, P. Warde, and C. Catton Salvage radiotherapy for PSA failure after radical prostatectomy Radiother Oncol 61 2 2001 107 116
26. A.J. Stephenson, P.T. Scardino, and M.W. Kattan Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 15 2007 2035 2041
27. N. Ohri, A.P. Dicker, E.J. Trabulsi, and T.N. Showalter Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling Eur J Cancer 48 6 2012 837 844
28. B. Djavan, S. Milani, and Y.K. Fong Benign positive margins after radical prostatectomy means a poor prognosis - pro Urology 65 2 2005 218 220
29. L. Liu, A.L. Coker, X.L. Du, J.N. Cormier, C.E. Ford, and S. Fang Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer J Surg Oncol 97 7 2008 583 591
30. M.B. Gretzer, B.J. Trock, M. Han, and P.C. Walsh A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria J Urol 168 4 Pt 1 2002 1419 1422
31. K.A. Roehl, M. Han, C.G. Ramos, J.A. Antenor, and W.J. Catalona Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 3 2004 910 914
32. J.E. McDermed, R. Sanders, and S. Fait Nucleic acid detection immunoassay for prostate-specific antigen based on immuno-PCR methodology Clin Chem 58 4 2012 732 740
33. F.V. Coakley, H.S. Teh, and A. Qayyum Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience Radiology 233 2 2004 441 448
34. E. Casciani, E. Polettini, and E. Carmenini Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy AJR Am J Roentgenol 190 5 2008 1187 1192
35. R.W. Ross, A.L. Zietman, and W. Xie Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy Clinical imaging 33 4 2009 301 305
36. M. Beheshti, R. Vali, and P. Waldenberger The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Mol Imaging Biol 12 1 2010 98 107
37. B.J. Beattie, P.M. Smith-Jones, and Y.S. Jhanwar Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET J Nucl Med 51 2 2010 183 192
38. E. Even-Sapir, U. Metser, E. Mishani, G. Lievshitz, H. Lerman, and I. Leibovitch The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT J Nucl Med 47 2 2006 287 297
39. G. Sonpavde, and G.S. Palapattu Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials Expert Rev Anticancer Ther 10 3 2010 439 450
40. M.D. Shelley, S. Kumar, T. Wilt, J. Staffurth, B. Coles, and M.D. Mason A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma Cancer Treat Rev 35 1 2009 9 17
41. W.F. Symmans, F. Peintinger, and C. Hatzis Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 28 2007 4414 4422
42. C.C. Schulman, F.M. Debruyne, G. Forster, F.P. Selvaggi, A.R. Zlotta, and W.P. Witjes 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer Eur Urol 38 6 2000 706 713
43. G. Aus, P.A. Abrahamsson, and G. Ahlgren Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial BJU Int 90 6 2002 561 566
44. C. Selli, R. Montironi, and A. Bono Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer J Clin Pathol 55 7 2002 508 513
45. R.K. Berglund, C.M. Tangen, and I.J. Powell Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109 Urology 79 3 2012 633 637
46. J. Chun, and R.S. Pruthi Is neoadjuvant hormonal therapy before radical prostatectomy indicated? Urol Int 72 4 2004 275 280
47. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 21 2011 1995 2005
48. M.E. Taplin, R.B. Montgomery, and C. Logothetis Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): results of a randomized phase II study J Clin Oncol 30 suppl 2012 abstr 4521
49. E.M. Messing, J. Manola, and J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 6 2006 472 479
50. S. Kumar, M. Shelley, C. Harrison, B. Coles, T.J. Wilt, and M.D. Mason Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 4) 2006 CD006019
51. W.U. Shipley, D. Hunt, and H. Lukka Initial report of RTOG 9601: a phase III trial in prostate cancer: anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3, NO disease, and elevated PSA levels Int J Radiat Oncol Biol Phys 78 3 2010 S27
52. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513 1520
53. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
54. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, Eisenberger, and I.F. Tannock Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 2008 242 245
55. R. Dreicer, C. Magi-Galluzzi, and M. Zhou Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer Urology 63 6 2004 1138 1142
56. P.G. Febbo, J.P. Richie, and D.J. George Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer Clin Cancer Res 11 14 2005 5233 5240
57. K.N. Chi, J.L. Chin, E. Winquist, L. Klotz, F. Saad, and M.E. Gleave Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer J Urol 180 2 2008 565 570
58. T. Prayer-Galetti, E. Sacco, and F. Pagano Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer BJU Int 100 2 2007 274 280
59. A. Sella, A. Zisman, S. Kovel, N. Yarom, D. Leibovici, and A. Lindner Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer Urology 71 2 2008 323 327
60. B. Mellado, A. Font, and A. Alcaraz Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer Br J Cancer 101 8 2009 1248 1252
61. J.A. Eastham, W.K. Kelly, G.D. Grossfeld, E.J. Small, and Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease Urology 62 Suppl 1 2003 55 62
62. S. Narita, N. Tsuchiya, and T. Kumazawa Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer World J Surg Oncol 10 2012 1
63. M. Hussain, D.C. Smith, and B.F. El-Rayes Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer Urology 61 4 2003 774 780
64. J.P. Machiels, F. Mazzeo, and M. Clausse Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer J Clin Oncol 26 32 2008 5261 5268
65. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial JAMA 299 3 2008 289-5
66. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2 2011 107 118
67. J. Laverdiere, A. Nabid, and L.D. De Bedoya The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer J Urol 171 3 2004 1137 1140
68. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610 J Clin Oncol 26 4 2008 585 591
69. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 11 2005 841 850
70. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 9327 2002 103 106
71. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 4 2001 937 946
72. T. Granfors, H. Modig, J.E. Damber, and R. Tomic Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone J Urol 176 2 2006 544 547
73. P. Warde, M. Mason, and K. Ding Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial Lancet 378 9809 2011 2104 2111
74. A. Widmark, O. Klepp, and A. Solberg Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial Lancet 373 9660 2009 301 308
75. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 15 2008 2497 2504
76. J. Crook, C. Ludgate, and S. Malone Final report of multicenter Canadian phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 73 2 2009 327 333
77. M. Bolla, T.M. de Reijke, and G. Van Tienhoven Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 24 2009 2516 2527
78. A.D. Sasse, E. Sasse, A.M. Carvalho, and L.T. Macedo Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review BMC Cancer 12 2012 54
79. F. Cuppone, E. Bria, and D. Giannarelli Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials BMC Cancer 10 2010 675
80. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 4 2008 980 988
81. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial JAMA 294 10 2005 1233 1239
82. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therpay in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 7 2010 1106 1111
83. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Lancet Oncol 8 6 2007 475 487
84. W.A. See, M.P. Wirth, and D.G. McLeod Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program J Urol 168 2 2002 429 435
85. C. Magi-Galluzzi, M. Zhou, A.M. Reuther, R. Dreicer, and E.A. Klein Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study Cancer 110 6 2007 1248 1254
86. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 9747 2010 1147 1154
87. H.I. Scher, X. Jia, and K. Chi Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer J Clin Oncol 29 16 2011 2191 2198
88. M.D. Michaelson, S. Oudard, and Y. Ou Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol 29 suppl 2011 abstr 4515
89. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
90. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 9768 2011 813 822
91. M.R. Smith, F. Saad, and R. Coleman Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 9810 2012 39 46
92. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Paper presented at ASCO 2012 Genitourinary Cancers Symposium. February 2-4, 2012, San Francisco Marriott Marquis, San Francisco, CA, USA.
93. W.K. Kelly, S. Halabi, and M. Carducci Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401 J Clin Oncol 30 13 2012 1534 1540
94. Scher H, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol. 2012;30 suppl 5: abstrLBA1
95. B.L. Chang, S.L. Zheng, and S.D. Isaacs Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer Prostate 56 1 2003 37 44
96. F. Wang, Y.F. Zou, X.L. Feng, H. Su, and F. Huang CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies Prostate 71 11 2011 1167 1177
97. B.L. Chang, S.L. Zheng, and G.A. Hawkins Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility Cancer Res 62 6 2002 1784 1789
98. N.J. Clegg, J. Wongvipat, and J.D. Joseph ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 6 2012 1494 1503
99. D. Pouessel, S. Oudard, G. Gravis, F. Priou, L. Shen, and S. Culine Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France Bull Cancer 99 7-8 2012 731 741
100. A.N. Serafini, S.J. Houston, and I. Resche Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial J Clin Oncol 16 4 1998 1574 1581
101. O. Sartor Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease Rev Urol 6 Suppl 10 2004 S3 12
102. T.A. Ferrara, J.W. Hodge, and J.L. Gulley Combining radiation and immunotherapy for synergistic antitumor therapy Curr Opin Mol Ther 11 1 2009 37 42
103. M.J. Gough, and M.R. Crittenden Combination approaches to immunotherapy: the radiotherapy example Immunotherapy 1 6 2009 1025 1037
104. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454